Warner LE; Mancias P; Butler IJ; et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat. Genet. 1998, 18 (4): 382–4. PMID 9537424. doi:10.1038/ng0498-382.
Warner LE, Svaren J, Milbrandt J, Lupski JR. Functional consequences of mutations in the early growth response 2 gene (EGR2) correlate with severity of human myelinopathies. Hum. Mol. Genet. 1999, 8 (7): 1245–51. PMID 10369870. doi:10.1093/hmg/8.7.1245.
Timmerman V; De Jonghe P; Ceuterick C; et al. Novel missense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype. Neurology. 1999, 52 (9): 1827–32. PMID 10371530.
Yoshihara T; Kanda F; Yamamoto M; et al. A novel missense mutation in the early growth response 2 gene associated with late-onset Charcot--Marie--Tooth disease type 1. J. Neurol. Sci. 2001, 184 (2): 149–53. PMID 11239949. doi:10.1016/S0022-510X(00)00504-9.
Boerkoel CF; Takashima H; Bacino CA; et al. EGR2 mutation R359W causes a spectrum of Dejerine-Sottas neuropathy. Neurogenetics. 2002, 3 (3): 153–7. PMID 11523566. doi:10.1007/s100480100107.
Yang Y; Dong B; Mittelstadt PR; et al. HIV Tat binds Egr proteins and enhances Egr-dependent transactivation of the Fas ligand promoter. J. Biol. Chem. 2002, 277 (22): 19482–7. PMID 11909874. doi:10.1074/jbc.M201687200.
Musso M; Balestra P; Taroni F; et al. Different consequences of EGR2 mutants on the transactivation of human Cx32 promoter. Neurobiol. Dis. 2003, 12 (1): 89–95. PMID 12609493. doi:10.1016/S0969-9961(02)00018-9.
Unoki M, Nakamura Y. EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK. Oncogene. 2003, 22 (14): 2172–85. PMID 12687019. doi:10.1038/sj.onc.1206222.
Numakura C; Shirahata E; Yamashita S; et al. Screening of the early growth response 2 gene in Japanese patients with Charcot-Marie-Tooth disease type 1. J. Neurol. Sci. 2003, 210 (1–2): 61–4. PMID 12736090. doi:10.1016/S0022-510X(03)00028-5.